A selective history of the therapy of Hodgkin's disease

British Journal of Haematology

Volumn 122, Issue 5, 2003, Pages 718-727

  DeVita Jr , Vincent T ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

ABVD; Clinical investigation; Combination chemotherapy; Complications (of therapy); Hodgkin's; MOPP

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; METHOTREXATE; NITROSOUREA DERIVATIVE; PREDNISONE; PROCARBAZINE; STREPTOZOCIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE;

CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HISTORY; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTORY, 20TH CENTURY; HODGKIN DISEASE; HUMANS; PORTRAITS;

EID: 0041912336     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04541.x     Document Type: Review

References (65)

1. Arseneau, J.C., Sponzo, R.W., Longo, D.L., Canellos, G.P. & DeVita, V.T. (1972) Non-lymphomatous malignant tumors complicating Hodgkin's disease: possible association with intensive therapy. New England Journal of Medicine., 287, 1119-1122.
2. Bagley, C.M., Young, R.C., Canellos, G.P. & DeVita, V.T. (1972) Treatment of ovarian carcinoma: possibilities for progress. New England Journal of Medicine, 287, 856-862.
3. Biti, G.P., Cimino, G., Cartoni, C., Magarini, S.M., Anselmo, A.P., Enrici, R.M., Bellesi, G.P., Bosi, A., Papa, G. & Giannarelli, D. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. Journal of Clinical Oncology, 10, 378-382.
4. Bollag, W. & Grunberg, E. (1963) Tumor inhibitory effects of a new class of cytotoxic agents; methyl hydrazine derivatives. Experientia, 19, 130-131.
5. Bonadonna, G., Monfardini, S., De Lena, M., Fossati Bellani, F. & Beretta, G. (1970) Phase I and preliminary phase II evaluation of adriamycin (NSC-123127). Cancer Research, 30, 2572-2582.
6. Bonadonna, G., Zucali, R., Monfardini, S. De Lena, M. & Uslenghi, C. (1975a) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycine, vinblastine and imidazole carboxamide versus MOPP. Cancer, 36, 252-259.
7. Bonadonna, G., Beretta, G., Tancini, G., Brambilla, C., Bajetta, E., De Palo, G.M. & Valagussa, P. (1975b) Adriamycine (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemotherapy Report, 6, 231-245.
8. Bonadonna, G., Valagussa, P. & Santoro, A. (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Annals of Internal Medicine, 104, 739-746.
9. Canellos, G.P. & Niedzwiecki, D. (2002) Long-term follow up of Hodgkin's disease trial. New England Journal of Medicine, 346, 417-418.
10. Canellos, G.P., DeVita, V.T., Gold, G.L., Chabner, B.A., Schein, P.S. & Young, R.C. (1974) Cyclical combination chemotherapy for advanced breast carcinoma. British Medical Journal, 1, 218-220.
11. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478-1484.
12. Carbone, P.P., Spurr, C., Schneiderman, M., Scott, J., Holland, J.F. & Shnider, B. (1968) Management of patients and malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Research, 28, 811-822.
13. Coltman, Jr, C.A., Frei, E. & Moon, T.E. (1976) MOPP maintenance (MM) vs (VMR) for MOPP induced complete remission (CR) of advanced Hodgkin's disease. Proceedings of the American Cancer Society, 17, 300.
14. Craft, C.B. (1940) Results with roentgen ray therapy in Hodgkin's disease. Bulletin of the Staff Meeting at the University of Minnesota Hospital, 11, 391-409.
15. Deisseroth, A.B. & DeVita, V.T. (1995) The cell cycle: probing new molecular determinants of resistance of sensitivity and cytotoxic agents. Cancer Journal from Scientific American, 1, 15-23.
16. DeVita, V.T. (1971) Cell kinetics and the chemotherapy of cancer. Cancer Chemotherapy Reports, Part, 3, 23-33.
17. DeVita, V.T. (1981) Consequences of the chemotherapy of Hodgkin's disease. Cancer, 47, 1-13.
18. DeVita, V.T. (1991) The influence of information on drug resistance on protocol design. The Henry Kaplan Lecture 4th International Conference on Malignant Lymphomas, June 6-9, 1990, Lugano, Switzerland. Annals of Oncology, 2, 93-106.
19. DeVita, V.T. & Schein, P.S. (1973) The use of drugs in combination for the treatment of cancer: rational and results. New England Journal of Medicine, 288, 998-1006.
20. DeVita, V.T., Moxley, J.H., Brace, K. & Frei, III, E. (1965a) Intensive combination chemotherapy and x-irradiation in the treatment of Hodgkin's disease. Proceedings of the American Association of Cancer Research, 6, 15-20.
21. DeVita, V.T., Hahn, M.A. & Olivorio, V.T. (1965b) Monoamine oxidase inhibition by a new carcinostatic agent, N-isopropyl-a (2-methyl-hydrazine)-p-toluamide (MIH). Proceedings of the Society of Experimental Biology and Medicine, 120, 561-565.
22. DeVita, V.T., Denham, C. & Perry, S. (1969a) Relationship of normal CDFI mouse leukocyte kinetics to growth characteristics of leukemia L1210. Cancer Research, 29, 1067-1071.
23. DeVita, V.T., Emmer, M., Levine, A., Jacobs, B. & Berard, C. (1969b) Pneumocystis carinii pneumonia: successful diagnosis and treatment of two patients with associated malignant processes. New England Journal of Medicine, 280, 287-291.
24. DeVita, V.T., Serpick, A. & Carbone, P.P. (1970) Combination chemotherapy in the treatment of advanced Hodgkin's disease. Annals of Internal Medicine, 73, 891-895.
25. DeVita, V.T., Arseneau, J.C., Sherins, R.J., Canellos, G.P. & Young, R.C. (1973) Intensive chemotherapy for Hodgkin's disease: long-term complications. National Cancer Institute Monograph, 36, 447-454.
26. DeVita, Jr, V.T., Canellos, G.P., Chabner, B., Schein, P., Hubbard, S.M. & Young, R.C. (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet, 1, 248-250.
27. DeVita, V.T., Simon, R.M., Hubbard, S.M., Young, R.C., Beard, C.W., Moxley, III, J.H., Carbone, P.P. & Canellos, G.P. (1980) Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP treated patients at NCI. Annals of Internal Medicine, 92, 587-595.
28. Diehl, V., Franklin, J., Hasenclever, D., Tesch, H., Pfreundschuh, M., Lathan, B., Paulus, U., Sieber, M., Rueffer, J.U., Sextro, M., Engert, A., Wolf, J., Hermann, R., Holmer, L., Stappert-Jahn, U., Winnerlein-Trump, E., Wuff, G., Krause, S., Glunz, A., von Kalle, K., Bischoff, H., Haedicke, C., Duehmke, E., Georgii, A. & Loeffler, M. (1998) BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology, 16, 3810-3821.
29. Easson, E.C. & Russell, M.H. (1963) The cure of Hodgkin's disease. British Medicine Journal, 5347, 1704-1707.
30. Fisher, R.I., DeVita, V.T., Hubbard, S.M., Simon, R. & Young, R.C. (1970) Prolonged disease free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals of Internal Medicine, 90, 761-763.
31. Fisher, R.I., DeVita, V.T., Bostick, F., Vanhaelen, C., Howser, D.M. & Hubbard, S.M. (1980) Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals of Internal Medicine, 92, 595-599.
32. Frei, III, E. & Freireich, E.J. (1965) Progress and perspectives in the chemotherapy of acute leukemia. Advances in Chemotherapy, 2, 269-298.
33. Frei, III, E., Luce, J.K., Talley, R.W., Vaitkevicius, V.K. & Wilson, H.E. (1972a) 5-(3,3-dimethyl-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemotherapy Reports, 56, 667-670.
34. Frei, III, E., Luce, J.K. & Gambel, J.E. (1972b) Combination chemotherapy in advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology and Therapeutics, 13, 750-754.
35. Gilbert, R. (1925) La roentgenthérapie de la granulomatose maligne. Journal of Radiologia Electrol, 9, 509-514.
36. Goldie, J.H. & Coldman, A.J. (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treatment Reports, 63, 1727-1733.
37. Huguley, Jr, C.M., Durant, J.R., Moores, R.R., Chann, Y.K., Dorfman, R. & Johnson, L. (1975) A comparison of nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease. Cancer, 36, 1227-1240.
38. Jacobs, E.M., Peters, F.C., Luce, J.K., Zippin, C. & Wood, D.A. (1968) Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. Journal of the American Medical Association, 203, 392-398.
39. Kaplan, H.S. (1962) The radical radiotherapy of regionally localized Hodgkin's disease. Radiology, 78, 553-561.
40. Kaplan, H.S. (1966) Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Research, 26, 1221-1224.
41. Kaplan, H.S. & Rosenberg, S.A. (1966) Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials. Cancer Research, 26, 1268-1276.
42. Kaplan, H.S., Dorfman, R.F., Nelsen, T.S. & Rosenberg, S.A. (1973) Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. National Institutes Monographs, 36, 291-301.
43. Klimo, P. & Connors, J. (1986) MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. Journal of Clinical Oncology, 3, 1174-1182.
44. Longo, D.L., Young, R.C., Wesley, M., Hubbard, S.M., Duffy, P.L., Jaffe, E.S. & DeVita, V.T. (1986) Twenty years of MOPP therapy for Hodgkin's disease. Journal of Clinical Oncology, 4, 1295-1305.
45. Longo, D.L., Glatstein, E., Duffey, P.L., Young, R.C., Hubbard, S.M., Urba, W.J., Wesley, M.N., Raubitschek, A., Jaffe, E.S. & Wiernik, P.H. (1991a) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. Journal of Clinical Oncology, 9, 906-917.
46. Longo, D.L., Duffey, P.L., DeVita, V.T., Wiernik, P.H., Hubbard, S.M., Phares, J.C., Bastian, A.W., Jaffee, E.S. & Young, R.C. (1991b) Treatment of advanced stage Hodgkin's disease: alternating non-cross-resistant MOPP/CABS is not superior to MOPP. Journal of Clinical Oncology, 9, 1409-1420.
47. Longo, D.L., Duffy, P.L., Young, R.C., Hubbard, S.M. & DeVita, V.T. (1992) Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy. Journal of Clinical Oncology, 10, 210-218.
48. Lukes, R.J. & Butler, J.J. (1966) The pathology and nomenclature of Hodgkin's disease. Cancer Research, 26, 1063-1083.
49. Mathe, G., Schweisguth, O. & Schnieder, M. (1963) Methylhydrazine in treatment of Hodgkin's disease and various forms of haematosarcoma and leukemia. Lancet, 2, 1077-1180.
50. Moore, M.R., Jones, S.E., Bull, J.M., William, L.A. & Rosenberg, S.A. (1973) MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients. Cancer, 32, 52-60.
51. Moxley, III, J.H. DeVita, V.T., Brace, K. Frei, III, E. (1967) Intensive combination chemotherapy and x-irradiation in Hodgkin's disease. Cancer Research, 27, 1258-1263.
52. Nicholson, W.M., Beard, M.E., Crowther, D., Stansfeld, A.G., Vartan, C.P., Malpas, J.S., Fairley, G.H. & Scott, R.B. (1970) Combination chemotherapy in generalized Hodgkin's disease. British Medical Journal, 3, 7-10.
53. Peters, M.V. (1950) A study of survivals in Hodgkin's disease treated radiologically. American Journal of Roentgenology, 63, 299-311.
54. Peters, M.V. (1966) Prophylactic treatment of adjacent areas in Hodgkin's disease. Cancer Research, 6, 1232-1243.
55. Peters, M.V. & Middlemiss, K.C. (1958) Study of survivals in Hodgkin's disease treated by irradiation. American Journal of Roentgenology, 79, 114-121.
56. Pusey, W.A. (1902) Cases of sarcoma and of Hodgkin's disease treated by exposure to x-rays: a preliminary report. Journal of the American Medical Association, 38, 166-169.
57. Rosenberg, S.A. & Kaplan, H.S. (1966) Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Research, 26, 1225-1231.
58. Santoro, A., Bonadonna, G., Bonfoante, V. & Valegusa, P. (1982) Alternating drug combinations in the treatment of advanced Hodgkin's disease. New England Journal of Medicine, 306, 770-775.
59. schilsky, R.L., Sherins, R.J., Hubbard, S.M. & DeVita, V.T. (1982) Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. American Journal of Medicine, 93, 109-114.
60. Scott, J.L. (1963) The effect of nitrogen mustard and maintenance chlorambucil in the treatment of advanced Hodgkin's disease. Cancer Chemotherapy Reports, 27, 27-32.
61. Sherins, R.J. & DeVita, V.T. (1973) Effects of drug treatment for treatment for lymphoma on male reproductive capacity: studies of men in remission after therapy. Annals of Internal Medicine, 79, 216-220.
62. Viviani, S., Santoro, A., Negretti, E., Bonfante, V., Valagussa, P. & Bonadonna, G. (1990) Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Annals of Oncology, 1, 123-127.
63. Yankee, R.A., DeVita, V.T. & Perry, S. (1967) The cell cycle of leukemia LI210 cells in vivo. Cancer Research, 27, 2381-2238.
64. Young, R.C. & DeVita, V.T. (1970) Cell cycle characteristics of human solid tumors in vivo. Cell Tissue Kinetics, 3, 285-295.
65. Young, R.C., Canellos, G.P., Chabner, B.A., Schein, P.S. & DeVita, V.T. (1973) Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet, 1, 1339-1343.